PAPILLARY RENAL CELL CARCINOMA
Clinical trials for PAPILLARY RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PAPILLARY RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for PAPILLARY RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo targets bone metastases in advanced kidney cancer
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to the standard treatment (cabozantinib) can improve outcomes for people with advanced kidney cancer that has spread to the bone. About 134 participants will receive either the combination or cabozantinib alone. The …
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
New drug duo shows promise against rare kidney cancers
Disease control OngoingThis study tests whether combining two drugs, nivolumab and cabozantinib, can shrink tumors in people with advanced or metastatic non-clear cell kidney cancer. About 60 adults who have had up to one prior treatment will receive the drug combination. The main goal is to see how ma…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:18 UTC
-
Triple-Drug cocktail targets rare kidney cancers
Disease control OngoingThis study tests whether a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow the growth of advanced or spreading kidney cancer in people with rare types of the disease. About 60 adults with non-clear cell kidney cancer that cannot be surgically …
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Bradley A. McGregor, MD • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Head-to-Head: which drug works better for rare kidney cancer?
Disease control OngoingThis study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at controlling the cancer. About 32 participants w…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
DNA in blood and urine may spot kidney cancers early
Diagnosis OngoingThis study collects blood, urine, and tissue samples from 589 people to find new DNA markers that could help detect kidney and urinary tract cancers earlier. Researchers are looking for specific changes in DNA methylation that are unique to these cancers. The goal is to develop a…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated May 17, 2026 04:35 UTC